ABSTRACT
Pancreas and kidney transplantation is the treatment of choice for patients with type 1 diabetes mellitus and terminal renal insufficiency. Herein we have presented a series of 35 patients transplanted between 2002 and 2009 including periods before and after 2007 divided based on introduction of some technical aspects. In the first phase (learning period) we have noted complications related to pancreatic surgery with a morbidity among 12 of 18 patients (66.6%). In the second period (stabilization period), complications appeared in 6 out of 17 patients (35.2%; P < .028). The reoperation rate was 83.3% in the learning period and 23.5% in the stabilization period (P < .03). Seven transplantectomies were performed in the first period (P < .004). Five patients died, all of them in the learning group (P < .019). Changes in the technical aspects of the procedure were responsible for improved outcomes obtained among pancreas and kidney transplantations.
Subject(s)
Kidney Transplantation/methods , Pancreas Transplantation/methods , Anastomosis, Surgical/methods , Diabetes Mellitus, Type 1/surgery , Diabetic Nephropathies/surgery , Glycated Hemoglobin/analysis , Humans , Intensive Care Units , Length of Stay , Organ Preservation Solutions , Pancreas Transplantation/adverse effects , Pancreas Transplantation/mortality , Postoperative Complications/epidemiology , Postoperative Complications/mortality , Survival AnalysisABSTRACT
Liver retransplantation (LReTx) is the therapeutic option for the irreversible failure of a hepatic graft. Our aim was to evaluate the rate of and indications for LReTx and actuarial patient survivals. Among 1260 LTx were 79 LReTx (6.3%). During the first LTx, there were no apparent differences between patients who did or did not required LReTx. The most frequent reasons were hepatic artery thrombosis (31.6%), recurrence of the VHC cirrhosis (30.4%), and primary graft failure (21.5%). The actuarial survivals at 1 and 5 years were 83% and 69% among those without LReTx versus 71% and 61% among early LReTx, and 64% and 34% among late LReTx (P < .001). Although there exists high morbidity and mortality with LReTx, it seems that this therapeutic alternative continues to be valid for patients with early hepatic loss, but not when the graft loss was late. It becomes necessary to define the minimal acceptable results that patient can benefit from LReTx.
Subject(s)
Liver Transplantation/statistics & numerical data , Reoperation/statistics & numerical data , Thrombosis/surgery , Cohort Studies , Follow-Up Studies , Hepatic Artery/pathology , Hepatitis C/complications , Hepatitis C/surgery , Humans , Kaplan-Meier Estimate , Liver Cirrhosis/mortality , Liver Cirrhosis/surgery , Liver Cirrhosis/virology , Liver Transplantation/mortality , Patient Selection , Recurrence , Survival Analysis , Survivors , Thrombosis/mortality , Time Factors , Treatment FailureABSTRACT
Liver retransplantation (LRT) is the only therapeutic option for the irreversible failure of a hepatic graft. The aim of this study was to evaluate our rate, indications, postoperative morbidity and mortality and patient survival at one and 5 years after LRT. 1,260 liver transplants (LT) were performed between 1991 and 2006, 79 were LRT (6.3%). During the first LT, there were no apparent differences between patients who did or did not require LRT. The most common reasons for LRT were hepatic artery thrombosis (31.6%), recurrence of hepatitis C virus cirrhosis (30.4%) and primary graft non function (21.5%). The actuarial survival rates at one and 5 years were 83% and 69% among those without LRT versus 71% and 61% among those with early LRT, and 64% and 34% among those with late LRT (p < 0.001). Although high morbidity and mortality were associated with LRT, it seems that this therapeutic option is valid for patients with early hepatic loss, although not when the graft loss is late. It becomes necessary to define the minimal acceptable results so that patients can benefit from LRT.
